PDXHCI002 - Cell Line (ID:51136)

HMS LINCS ID: 51136
Name: PDXHCI002
Alternative Names:
LINCS ID:
Alternative ID:
Parent Cell Line:
Reference Source: Dan Stover (Harvard Medical School)
Organism: Homo sapiens
Organ: breast
Tissue:
Cell Type: epithelial
Details of Cell Type:
Donor Sex: female
Donor Age:
Donor Ethnicity:
Donor Health Status:
Disease: DOID: 3008, IDC
Details of Disease: poorly differentiated, medullary type, stage 3A
Production Details:
Genetic Modification(s): none
Known Mutations:
Citation Information for Mutations:
Verification Reference Profile: DNA Profile (STR): Amelogenin: X CSF1PO: 10 D13S317: 9,12 D16S539: 12 D5S818: 12 D7S820: 8,11 THO1: 6,8 TPOX: 8,11 vWA: 17,19
Growth Properties: adherent
Recommended Culture Conditions: Cells are cultured in F-media: 3:1 mix of complete Dulbecco's MEM (containing 10% fetal bovine serum, 1% penicillin/streptomycin) and Ham's F12 suplemented with 0.125 ng/ml epidermal growth factor, 25 ng/ml hydrocortisone, 5 ug/ml insulin, 8.6 ng/ml cholera toxin, and 5 uM Y-27632 (HMSLID 10176). Protocol: Aspirate spent culture medium, wash cells once with PBS, trypsinize cells with 0.25% trypsin, collect trypsinized cells. Centrifuge at 300 x g for 5 min. Resuspend the cell pellet in F-media, and transfer to fresh plates or flasks. A cubcultivation ratio of 1:2 to 1:6 recommended.
Relevant Citations: PMID 22019887
Usage Note:
Comments: Established by Dan Stover (Joan Brugge Lab, Harvard Medical School) from a PDX tumor (Alana Welm Lab, University of Utah)
Date Publicly Available: 2018-03-27
Most Recent Update: 2018-03-27

Datasets:

HMS Dataset ID Dataset Title HMS Dataset Type
20343
Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values
Microscopy/Imaging
20344
Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics
Analysis
20348
Breast Cancer Profiling Project, Gene Expression 1: Baseline mRNA sequencing on 35 breast cell lines
RNA-Seq
20350
Breast Cancer Deubiquitinating Enzyme (DUB) Inhibitor Profiling: Fixed-cell GR measures of 21 breast cell lines to 32 small molecule perturbagens. Dataset 1 of 2: Normalized growth rate inhibition values.
Microscopy/Imaging
20351
Breast Cancer Deubiquitinating Enzyme (DUB) Inhibitor Profiling: Fixed-cell GR measures of 21 breast cell lines to 32 small molecule perturbagens. Dataset 2 of 2: Calculated dose response metrics.
Analysis
20352
Breast Cancer Profiling Project – Proteomics 1: 1 total proteome dataset for a 35-cell line breast cancer panel under basal conditions
Proteomics
20353
Breast Cancer Profiling Project – Proteomics 2: 1 phosphoproteome dataset (including phosphotyrosine enrichment) for a 35-cell line breast cancer panel under basal conditions
Proteomics
20373
DGE-seq Gene expression data for 7 breast cancer cell lines treated with abemaciclib, palbociclib, ribociclib at 0.1, 0.3, 1, or 3 μM, or alvocidib at 0.1 or 1 μM for 6 hours
RNA-Seq

Batch Information:

HMS LINCS Batch ID Provider Provider Catalog ID Provider Batch ID
51136-1 Dan Stover (Harvard Medical School)